PATENT CLAIM ANALYSIS

Application Number: 16133025
Application Type: Utility
Filing Date: 2018-09
Publication Date: 2019-03
Patent Classification: ["424", "134100"]

Abstract:
This application provides anti-PCSK9˜GLP-1 fusions and methods for use.

Claim (Index 30):
A method of reducing low density lipoprotein (LDL) in a subject comprising administering to a subject in need thereof, a dual active fusion molecule comprising an anti-PCSK9 antibody stably fused to a GLP-1 peptide, wherein the anti-PCSK9 antibody binds a PCSK9 polypeptide and the GLP-1 peptide binds a GLP-1 receptor.

Metadata:
- Claim Count in Document: 8.0
- Percentile: 97.0
- Lexical Diversity: 1.0
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15117985', '12965743', '13918755', '16102552', '13225265']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7296634579779516
- 35 USC 102 Novelty (BERT): 0.6429978600766975
- Combined Prediction Score: 0.7209968981878262
- Mean Citation Score: 354.9907100000001
- Max Citation Score: 697.0958
- Similarity Product: 550.6743265966653

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test